Atara Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Atara Biotherapeutics, Inc. on February 3, 2023, with the earliest event reported on the same date. The filing primarily addresses executive leadership changes and references the announcement of financial results for the fourth quarter and full year ended December 31, 2022, which were released on February 8, 2023.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not detailed in the body of this 8-K. The filing explicitly states that the information in the press release is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Material Changes and Executive Transitions
- Departure of CFO: Utpal Koppikar, Executive Vice President and Chief Financial Officer, notified the Company of his resignation effective March 31, 2023, to pursue an external opportunity.
- Appointment of New CFO: Eric Hyllengren, Senior Vice President, Finance, was appointed as Senior Vice President, Chief Financial Officer, effective April 1, 2023. He will also serve as Principal Financial Officer and Principal Accounting Officer.
- Compensation: Mr. Hyllengren's base salary is set at $455,000 with a bonus target equal to 40% of his base salary.
Outlook, Risks, and Contingencies
The filing does not contain specific guidance, outlook, or risk factors beyond the standard disclosure regarding the executive transition. The Company noted that Mr. Hyllengren joined Atara in 2018 and previously spent 15 years at Amgen Inc. The transition is planned to ensure continuity in financial leadership.
Key Facts for Investor Verification
- Verify the specific financial results for Q4 and full-year 2022 by reviewing the press release dated February 8, 2023 (Exhibit 99.1), as this 8-K does not list the figures.
- Confirm the effective dates of the CFO transition: Utpal Koppikar's departure on March 31, 2023, and Eric Hyllengren's appointment on April 1, 2023.
- Review the Executive Employment Agreement and Indemnification Agreement referenced in the Company's Form 10-K filed on February 8, 2023, for full terms of Mr. Hyllengren's compensation.